ORIC Pharmaceuticals grants stock options and restricted units to new hires under Nasdaq rules.

ORIC Pharmaceuticals granted 216,000 stock options and 35,000 restricted stock units to four new non-executive employees who joined in April 2026. These inducement grants, approved under Nasdaq Listing Rule 5635(c)(4), are designed to incentivize employment and vest over time based on continued service. The stock options have an exercise price set at the closing stock price on May 1, 2026. This move supports ORIC's growth as a clinical-stage oncology company developing cancer treatments, signaling ongoing investment in talent to advance its pipeline.